Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,878 JPY | +1.57% | +3.33% | +6.76% |
Apr. 25 | Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln | RE |
Apr. 15 | Neumora's early-stage schizophrenia drug study put on hold | RE |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- This company will be of major interest to investors in search of a high dividend stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in debt and has limited leeway for investment
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Wireless Telecommunications Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.76% | 56.67B | A- | ||
+28.33% | 94.52B | C+ | ||
-11.97% | 23.64B | A- | ||
-16.38% | 20.55B | C | ||
-12.50% | 11.16B | C | ||
+5.61% | 10.64B | C | ||
+2.45% | 10.28B | B+ | ||
+0.88% | 8.9B | B+ | ||
-25.24% | 8.29B | B- | ||
+20.93% | 6.61B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 9434 Stock
- Ratings SoftBank Corp.